BALTIMORE, MD--(Marketwired - Jul 1, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that with some of the biggest stories in breast cancer of late having nothing to do with treatment development success, patients potentially at risk for the disease would likely prefer to learn more about new treatment options under development, such as the therapy designed by Nuvilex, Inc. (OTCQB: NVLX).
For example, breast cancer patients have been treated with word that Hollywood starlet Angelina Jolie recently underwent a double mastectomy as a preventive measure, prompting many at-risk women to consider the same procedure. While Ms. Jolie's admission is noble and admirable, the American Cancer Society has urged caution against such surgeries, especially given that the risk of developing cancer may not be eliminated.
Conversely, results from Phase I/II clinical trials in dogs conducted by Nuvilex affiliate SG Austria's, which are closely related to the development of breast cancer in humans, were remarkably similar to its well-known human Phase II pancreatic cancer trial. For example, greater degrees of tumor shrinkage were observed in those dogs treated with encapsulated pro-drug-activating cells as well as the pro-drug cyclophosphamide versus those receiving cyclophosphamide alone. In the case where two spontaneous mammary tumors grew in the same animal, one tumor was treated with cyclophosphamide alone and the other was treated with the encapsulated cell/cyclophosphamide combination. The combination treatment resulted in 70% tumor shrinkage as compared to the 20% shrinkage seen with the drug alone.
It is evident that the results of this animal trial could lead to a future human breast cancer clinical trial using the Company's live-cell encapsulation platform, which should be viewed as a major development given the different approach engaged by Nuvilex, along with its results, as compared with current therapies. The bottom line is that the Company's 2 trials clearly illustrate the great potential efficacy in using encapsulated cells with a pro-drug as a targeting device for the treatment of solid pancreatic and mammary tumors, which will substantially raise Nuvilex's profile and valuation.
A copy of this article as well as other articles and Nuvilex reports and disclaimers can be accessed by visiting www.goldmanresearch.com.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Nuvilex, Inc. (OTCQB: NVLX): Nuvilex, Inc. has been a provider of all-natural products for many years, has expanded its company to increase its natural product based footprint through medical marijuana studies and is becoming an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for treatments, research and medicine. The Company's offerings will ultimately include cancer, diabetes and other clinical treatments using the company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development. For more information visit: www.nuvilex.com.